In the US, about one million people with diabetes per year are treated for foot ulcers.

Current treatment involves the use of various skin substitutes which are able to improve wound healing in the short term but have limited long-term success due to the lack of blood vessels to deliver enough oxygen and nutrients.

Angioblast plans to develop an MPC product on a biocompatible patch which will be the only product in the market capable of providing both increased blood supply and new cells to repair and regenerate the wound site.

The Technology

 

Last Share Price

January 06 - Mesoblast Named 2009 North American Emerging Company By Frost And Sullivan

November 27 - Executive Director's Presentation at the AGM

November 27 - Chairman's speech to AGM

November 24 - Investor Briefing – The CEO Transcript

May 2008 - Issue Nine

September 2007 - Issue Eight

March 2007 - Issue Seven

August 2006 - Issue Six